SG11201407591PA - Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof - Google Patents
Process of making hydroxylated cyclopentapyrimidine compounds and salts thereofInfo
- Publication number
- SG11201407591PA SG11201407591PA SG11201407591PA SG11201407591PA SG11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA
- Authority
- SG
- Singapore
- Prior art keywords
- genentech
- california
- south san
- international
- san francisco
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- LTFBFZBWUKWXID-UHFFFAOYSA-N 1h-cyclopenta[d]pyrimidine Chemical class N1=CNC2=CC=CC2=C1 LTFBFZBWUKWXID-UHFFFAOYSA-N 0.000 title abstract 2
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 abstract 1
- 101000582929 Homo sapiens Plasmolipin Proteins 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100030265 Plasmolipin Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 hydroxylated cyclopentapyrimidine com pounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000003197 protein kinase B inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648535P | 2012-05-17 | 2012-05-17 | |
| PCT/US2013/041695 WO2013173784A1 (fr) | 2012-05-17 | 2013-05-17 | Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407591PA true SG11201407591PA (en) | 2015-01-29 |
Family
ID=48534508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407591PA SG11201407591PA (en) | 2012-05-17 | 2013-05-17 | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9315471B2 (fr) |
| EP (1) | EP2850200A1 (fr) |
| JP (1) | JP6355625B2 (fr) |
| KR (1) | KR102123131B1 (fr) |
| CN (1) | CN104471070B (fr) |
| AU (1) | AU2013262521B2 (fr) |
| BR (1) | BR112014028573B1 (fr) |
| CA (1) | CA2873661C (fr) |
| IL (1) | IL235699B (fr) |
| MA (1) | MA37647A1 (fr) |
| MX (1) | MX354373B (fr) |
| MY (1) | MY169029A (fr) |
| NZ (1) | NZ702950A (fr) |
| RU (1) | RU2642311C2 (fr) |
| SG (1) | SG11201407591PA (fr) |
| WO (1) | WO2013173784A1 (fr) |
| ZA (1) | ZA201409226B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173811A1 (fr) | 2012-05-17 | 2013-11-21 | Genentech, Inc. | Forme amorphe d'un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci |
| SI2861582T1 (sl) | 2012-05-17 | 2016-09-30 | Array Biopharma, Inc. | Postopek za izdelavo hidroksiliranih ciklopentilpirimidinskih spojin |
| CA2873658C (fr) | 2012-05-17 | 2021-01-26 | Genentech, Inc. | Procede de preparation de composes d'acides amines |
| DK2861583T3 (en) | 2012-05-17 | 2016-10-03 | Array Biopharma Inc | METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER |
| PL3656764T3 (pl) * | 2013-11-15 | 2024-01-22 | F. Hoffmann-La Roche Ag | Sposoby przygotowania związków pirymidynylocyklopentanu |
| AR102088A1 (es) * | 2014-09-26 | 2017-02-01 | Genentech Inc | Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina |
| MX2019001579A (es) | 2016-08-10 | 2019-06-20 | Hoffmann La Roche | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. |
| CN110268067A (zh) * | 2016-08-16 | 2019-09-20 | 伊美格生物科学公司 | 用于产生立体异构纯的氨基环丙烷的组合物和方法 |
| WO2019122421A1 (fr) * | 2017-12-22 | 2019-06-27 | Astrazeneca Ab | Réduction stéréosélective de cétone à l'aide d'une enzyme cétoréductase |
| WO2022017448A1 (fr) * | 2020-07-22 | 2022-01-27 | 南京正大天晴制药有限公司 | Sel et forme cristalline de dérivé de dihydropyrido[2,3-d]pyrimidine |
| CN115916350B (zh) * | 2020-07-22 | 2024-11-05 | 南京正大天晴制药有限公司 | Akt抑制剂的单位剂量组合物 |
| WO2023043869A1 (fr) | 2021-09-15 | 2023-03-23 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide de citrate d'ipatasertib |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0732874A4 (fr) | 1993-12-12 | 1998-10-07 | Agrogene Ltd | Nouveau procede servant a proteger des vegetaux des infections fongiques |
| AU724216B2 (en) | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
| US6201023B1 (en) | 1997-06-10 | 2001-03-13 | Agrogene Ltd. | Methods and compositions to protect crops against plant parasitic nematodes |
| EP0918090A3 (fr) * | 1997-11-04 | 2002-08-28 | Eli Lilly And Company | Cétoreductase gène et protéine de levure |
| EP0982300A3 (fr) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique |
| AU3386600A (en) | 1999-03-03 | 2000-09-21 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2001022963A1 (fr) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Procede de prevention de l'osteoporose |
| DE10119274A1 (de) * | 2001-04-20 | 2002-10-31 | Juelich Enzyme Products Gmbh | Enzymatisches Verfahren zur enantioselektiven Reduktion von Ketoverbindungen |
| CA2526506A1 (fr) | 2003-06-09 | 2004-12-16 | Boehringer Ingelheim International Gmbh | Inhibiteurs du papillomavirus |
| KR100959771B1 (ko) * | 2005-06-10 | 2010-05-28 | 머크 샤프 앤드 돔 코포레이션 | Ａｋｔ 활성의 억제제 |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| WO2009036404A2 (fr) * | 2007-09-13 | 2009-03-19 | Codexis, Inc. | Polypeptides de cétoréductase pour la réduction d'acétophénones |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| JP5539225B2 (ja) * | 2008-01-09 | 2014-07-02 | アレイ バイオファーマ、インコーポレイテッド | Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン |
| CN102459165B (zh) | 2009-04-15 | 2015-09-02 | Abbvie公司 | 抗病毒化合物 |
| MX2012004780A (es) | 2009-10-23 | 2012-08-23 | Lilly Co Eli | Inhibidores de akt. |
| EP2592933B1 (fr) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Inhibiteurs mif et leurs utilisations |
| WO2012177925A1 (fr) | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3 |
| SI2861582T1 (sl) | 2012-05-17 | 2016-09-30 | Array Biopharma, Inc. | Postopek za izdelavo hidroksiliranih ciklopentilpirimidinskih spojin |
| CA2873658C (fr) | 2012-05-17 | 2021-01-26 | Genentech, Inc. | Procede de preparation de composes d'acides amines |
| DK2861583T3 (en) | 2012-05-17 | 2016-10-03 | Array Biopharma Inc | METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER |
| CA2889855A1 (fr) | 2012-11-01 | 2014-05-08 | Robert S. Katz | Methodes de traitement de la fibromyalgie |
| US20150376198A1 (en) | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| BR112015023193A2 (pt) | 2013-03-15 | 2017-07-18 | Shifa Biomedical Corp | usos de um composto e de um modulador, e, composto |
-
2013
- 2013-05-17 RU RU2014151014A patent/RU2642311C2/ru active
- 2013-05-17 MY MYPI2014703414A patent/MY169029A/en unknown
- 2013-05-17 JP JP2015512904A patent/JP6355625B2/ja active Active
- 2013-05-17 BR BR112014028573-0A patent/BR112014028573B1/pt active IP Right Grant
- 2013-05-17 KR KR1020147035265A patent/KR102123131B1/ko active Active
- 2013-05-17 EP EP13725535.2A patent/EP2850200A1/fr active Pending
- 2013-05-17 CA CA2873661A patent/CA2873661C/fr active Active
- 2013-05-17 WO PCT/US2013/041695 patent/WO2013173784A1/fr active Application Filing
- 2013-05-17 NZ NZ702950A patent/NZ702950A/en not_active IP Right Cessation
- 2013-05-17 AU AU2013262521A patent/AU2013262521B2/en active Active
- 2013-05-17 CN CN201380037997.1A patent/CN104471070B/zh active Active
- 2013-05-17 MX MX2014013855A patent/MX354373B/es active IP Right Grant
- 2013-05-17 SG SG11201407591PA patent/SG11201407591PA/en unknown
- 2013-05-17 US US14/401,089 patent/US9315471B2/en active Active
- 2013-05-17 MA MA37647A patent/MA37647A1/fr unknown
-
2014
- 2014-11-13 IL IL235699A patent/IL235699B/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09226A patent/ZA201409226B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104471070A (zh) | 2015-03-25 |
| KR102123131B1 (ko) | 2020-06-15 |
| JP2015518715A (ja) | 2015-07-06 |
| AU2013262521A1 (en) | 2015-01-22 |
| CN104471070B (zh) | 2018-09-25 |
| AU2013262521B2 (en) | 2017-03-02 |
| IL235699A0 (en) | 2015-01-29 |
| EP2850200A1 (fr) | 2015-03-25 |
| CA2873661A1 (fr) | 2013-11-21 |
| US9315471B2 (en) | 2016-04-19 |
| BR112014028573B1 (pt) | 2021-11-16 |
| MY169029A (en) | 2019-02-04 |
| WO2013173784A1 (fr) | 2013-11-21 |
| RU2642311C2 (ru) | 2018-01-24 |
| US20150099880A1 (en) | 2015-04-09 |
| MX354373B (es) | 2018-02-28 |
| NZ702950A (en) | 2016-09-30 |
| HK1208500A1 (en) | 2016-03-04 |
| BR112014028573A2 (pt) | 2018-04-24 |
| IL235699B (en) | 2018-12-31 |
| KR20150018579A (ko) | 2015-02-23 |
| MA37647A1 (fr) | 2016-03-31 |
| JP6355625B2 (ja) | 2018-07-11 |
| CA2873661C (fr) | 2020-07-21 |
| MX2014013855A (es) | 2016-03-21 |
| RU2014151014A (ru) | 2016-07-10 |
| ZA201409226B (en) | 2017-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201403402VA (en) | Compounds | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201407613RA (en) | Process for making hydroxylated cyclopentylpyrimidine compounds | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201407618VA (en) | Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof |